Immunome (IMNM) Change in Accured Expenses (2019 - 2026)

Immunome has reported Change in Accured Expenses for 8 years, with the latest figure at -$9.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 14.38% year-over-year to -$9.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (down 24.13% YoY), and the FY2025 full-year result was $4.5 million, down 66.55% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$9.7 million, down from $5.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $6.9 million in Q2 2024, with the low at -$9.7 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $413470.6 across 5 years, with a median of $619000.0 in 2025.
• The largest YoY upside for Change in Accured Expenses was 13155.81% in 2025 against a maximum downside of 1373.69% in 2025.
• Immunome's Change in Accured Expenses stood at $549000.0 in 2022, then jumped by 276.32% to $2.1 million in 2023, then sank by 97.92% to $43000.0 in 2024, then surged by 13155.81% to $5.7 million in 2025, then sank by 270.98% to -$9.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$9.7 million (Q1 2026), $5.7 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.